Price Elasticity of Demand: Elastic, Inelastic, and Revenue Implications

A 10% Price Hike. What Happens Next?

When Uber raised surge prices during a 2013 New York City blizzard, taxi rides became cheaper alternatives overnight and passengers flooded toward them. When insulin manufacturers raised list prices by over 600% between 1996 and 2019 — from roughly $21 to $335 per vial — diabetic patients did not substantially reduce usage; they rationed doses, cut food spending, and went into debt. Two markets. Two radically different responses to the same policy mechanism. The difference is price elasticity of demand, one of the most practical quantitative tools in economics.

Price elasticity of demand (PED) measures the percentage change in quantity demanded divided by the percentage change in price. A PED of −2.0 means a 1% price increase causes a 2% fall in quantity demanded. A PED of −0.3 means the same price change produces only a 0.3% decline in demand. The sign is always negative (price and demand move inversely), so economists typically discuss the absolute value.

Elastic vs. Inelastic: The Critical Threshold

The revenue implications diverge sharply across these categories. For elastic goods, raising price reduces total revenue (TR = P × Q) because the volume decline outweighs the higher price. For inelastic goods, raising price increases total revenue because demand barely falls. This explains why governments tax alcohol, tobacco, and fuel heavily — inelastic demand ensures revenue holds even at high prices — and why pharmaceutical companies charging life-saving drug prices face minimal volume loss from price increases.

Key Determinants of Elasticity

• Availability of substitutes: The most powerful determinant. Coke becomes highly elastic if Pepsi is visible on the same shelf; insulin has no effective substitute for type 1 diabetics
• Share of income: Goods that represent a large fraction of household income (housing, cars) tend to be more price-sensitive than trivial purchases (matches, paper clips)
• Necessity vs. luxury: Necessities tend toward inelasticity; luxuries toward elasticity — though this spectrum is culturally contingent
• Time horizon: Long-run elasticity exceeds short-run elasticity. After a petrol price spike, consumers cannot immediately buy fuel-efficient cars; over five years, they can and do
• Definition of the market: "Food" is inelastic; "Mexican restaurants in Chicago" is highly elastic

Cross-Price Elasticity of Demand

Cross-price elasticity (XED) measures how quantity demanded for good A changes when the price of good B changes. XED = % change in QD of A ÷ % change in price of B.

XED is central to antitrust analysis. Regulators use XED estimates to define relevant markets: if two goods have high positive XED, they are close substitutes and belong in the same market for merger review purposes. The FTC's 2004 analysis of Whole Foods' acquisition of Wild Oats hinged partly on whether premium natural/organic grocery chains formed a distinct market from conventional supermarkets.

Giffen Goods: The Paradox

A Giffen good violates the law of demand: quantity demanded rises when price increases. Robert Giffen allegedly observed this in 19th-century Ireland, where Irish peasants ate more potatoes when potato prices rose because the price increase made them poorer, and potatoes (the cheapest calorie source) were all they could afford. The empirical evidence for historical Giffen goods is contested — Charles Read and others have argued the Irish potato famine data do not cleanly support the mechanism.

The strongest empirical evidence comes from a field experiment by Robert Jensen and Nolan Miller published in American Economic Review (2008) in Hunan and Gansu provinces of China, where rice and wheat flour subsidies were provided and subsequently removed. When rice prices fell in Hunan, poorer households bought less rice — consistent with Giffen behavior. The Giffen mechanism requires: the good must be a significant portion of income, the consumer must be very poor, and no close substitute must exist.

Drug Pricing and Inelasticity

The pharmaceutical market provides the clearest real-world laboratory for extreme inelasticity. A 2020 analysis in JAMA Internal Medicine estimated the price elasticity of insulin demand at approximately −0.15 to −0.30 in the short run among non-low-income patients, and close to zero among patients who would face immediate health consequences from dose reduction. Manufacturers exploit this inelasticity through list price escalation, while pharmacy benefit managers negotiate rebates that are not passed to patients. The result: list prices rose an average of 15.5% annually from 2012 to 2016 while rebates absorbed most of the nominal price increase but left uninsured patients paying full list prices.

The 2022 Inflation Reduction Act capped Medicare insulin cost-sharing at $35/month — an external price control that effectively counteracted the inelasticity-based pricing strategy by removing the consumer's price exposure rather than altering the underlying demand curve. For economists, this illustrates that when demand inelasticity stems from medical necessity rather than preference, market-based price setting produces welfare outcomes that most democratic societies find unacceptable.